$1.08
0.02[1.89%]
At close: May 17
Lineage Cell Therapeutics
(AMEX:LCTX)Lineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, Predictions
Lineage Cell Therapeutics Inc has a consensus price target of $6.17, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 6, 2024, March 8, 2024, and February 13, 2024. With an average price target of $7 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 548.15% upside for Lineage Cell Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
HC Wainwright & Co.
Baird
B. Riley Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Lineage Cell Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2024 | Buy Now | 455.56% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 455.56% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2023 | Buy Now | 548.15% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 548.15% | HC Wainwright & Co. | — | → $7 | Reiterates | → Buy | Get Alert |
| 11/02/2022 | Buy Now | 362.96% | Baird | Jack Allen | → $5 | Initiates | → Outperform | Get Alert |
| 06/14/2022 | Buy Now | 270.37% | B. Riley Securities | Mayank Mamtani | → $4 | Initiates | → Buy | Get Alert |
| 08/19/2021 | Buy Now | 640.74% | Noble Capital Markets | Robert LeBoyer | → $8 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Lineage Cell Therapeutics (LCTX)?
The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by HC Wainwright & Co. on May 6, 2024. The analyst firm set a price target for $7.00 expecting LCTX to rise to within 12 months (a possible 548.15% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?
The latest analyst rating for Lineage Cell Therapeutics (AMEX: LCTX) was provided by HC Wainwright & Co., and Lineage Cell Therapeutics reiterated their buy rating.
When was the last upgrade for Lineage Cell Therapeutics (LCTX)?
There is no last upgrade for Lineage Cell Therapeutics.
When was the last downgrade for Lineage Cell Therapeutics (LCTX)?
There is no last downgrade for Lineage Cell Therapeutics.
When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on May 6, 2024 so you should expect the next rating to be made available sometime around May 6, 2025.
Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?
While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a reiterated with a price target of $0.00 to $7.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $1.08, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.